Mind Medicine (MindMed) Inc. (MNMD)
Mind Medicine (MindMed) Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Vancouver, BC, CA. The stock last traded at $20.69, up 0.44% on the session, giving a market capitalisation of $1.56B. On trailing twelve-month figures it carries a trailing P/E of -6.01, a net margin of 0.0%. Its beta of 2.62 implies it has historically moved more than the broad market.
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering new treatments for various brain health conditions, encompassing psychiatric disorders, addiction, pain, and neurological ailments. Among its key pipeline assets is MM-120, currently undergoing Phase 2 clinical trials. This candidate is being investigated for its potential in addressing generalized anxiety disorder, attention deficit hyperactivity disorder (ADHD), and chronic pain. Furthermore, MM-110, an a3ß4 nicotinic cholinergic receptor antagonist, has successfully completed Phase 1 studies for managing opioid withdrawal. The company's portfolio also includes MM-402, an R-enantiomer of 3,4-methylenedioxymethamphetamine, aimed at treating the core symptoms associated with autism spectrum disorder. Its corporate headquarters are situated in Vancouver, Canada.
Mind Medicine (MindMed) Inc. is most often compared with the following Healthcare names: